Cardinal Health reported better-than-expected Q4 adjusted earnings and provided an upbeat fiscal 2027 outlook, leading to a significant jump in its stock price. The company also announced an expanded share repurchase program and highlighted its growing dominance in the cell and gene therapy market, signaling strong future growth prospects.
Cardinal Health (CAH) delivered a strong Q4 earnings beat on adjusted EPS and, more importantly, issued an optimistic fiscal 2027 earnings outlook that surpassed analyst expectations. This positive guidance, coupled with a significant $5 billion increase in its share repurchase authorization, signals management's confidence in future performance and commitment to shareholder returns. The company's growing exclusive market share in the high-growth cell and gene therapy sector (nearly half the market) represents a key long-term growth driver and competitive advantage. For traders, this indicates a strong bullish sentiment for CAH in the short term due to the earnings beat and guidance, with long-term opportunities driven by its strategic positioning in specialized healthcare markets. The renewed agreement with Kroger (KR) is a stable, but less impactful, development.